Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
popular GLP-1 weight loss drugs reshape human health
Massive study looks at benefits, risks of GLP-1 weight-loss drugs
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections, some kinds of cancer and dementia,
GLP-1 weight loss drugs linked to a wide range of health benefits and risks: study
A new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and risks, including several newly found conditions linked to the GLP-1 class of weight loss and diabetes drugs.
Grazia Daily
1h
Oprah Winfrey Says Weight-Loss Drugs Have Changed Her Perception Of ‘Thin’ People
Oprah Winfrey has admitted to using an unnamed weight-loss drug to manage her weight and says doing so has changed her ...
Face2FaceAfrica on MSN
15h
Oprah Winfrey reveals how weight-loss drug helped her realize the truth about ‘thin people’
Oprah Winfrey says taking weight-loss medications like Ozempic and Wegovy challenged and helped her understand the truth ...
phillyvoice.com
1d
Ozempic and Wegovy are helping many Americans lose weight, but they also may have other beneficial uses
News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...
2d
on MSN
Largest-ever Ozempic and GLP-1 drug study finds they lower risk of 42 health conditions, including heart attacks and Alzheimer’s disease
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback